Cargando…

Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer

Colorectal cancer (CRC) is the third most common malignant tumor. DNA damage plays a crucial role in tumorigenesis, and abnormal DNA repair pathways affect the occurrence and progression of CRC. In the current study, we aimed to construct a DNA repair-related gene (DRG) signature to predict the over...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Dingli, Zhang, Dai, Chen, Sisi, Wu, Jie, Hao, Qian, Zhao, Lili, Ren, Hong, Du, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050689/
https://www.ncbi.nlm.nih.gov/pubmed/35484177
http://dx.doi.org/10.1038/s41598-022-10561-w
_version_ 1784696424512880640
author Song, Dingli
Zhang, Dai
Chen, Sisi
Wu, Jie
Hao, Qian
Zhao, Lili
Ren, Hong
Du, Ning
author_facet Song, Dingli
Zhang, Dai
Chen, Sisi
Wu, Jie
Hao, Qian
Zhao, Lili
Ren, Hong
Du, Ning
author_sort Song, Dingli
collection PubMed
description Colorectal cancer (CRC) is the third most common malignant tumor. DNA damage plays a crucial role in tumorigenesis, and abnormal DNA repair pathways affect the occurrence and progression of CRC. In the current study, we aimed to construct a DNA repair-related gene (DRG) signature to predict the overall survival (OS) of patients with CRC patients. The differentially expressed DRGs (DE-DRGs) were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The prognostic gene signature was identified by univariate Cox regression and least absolute shrinkage and selection operator (LASSO)-penalized Cox proportional hazards regression analysis. The predictive ability of the model was evaluated using the Kaplan–Meier curves and time-dependent receiver operating characteristic (ROC) curves. The gene set enrichment analysis (GSEA) was performed to explore the underlying biological processes and signaling pathways. ESTIMATE and CIBERSORT were implemented to estimate the tumor immune score and immune cell infiltration status between the different risk group. The half-maximal inhibitory concentration (IC50) was evaluated to representing the drug response of this signature. Nine DE-DRGs (ESCO2, AXIN2, PLK1, CDC25C, IGF1, TREX2, ALKBH2, ESR1 and MC1R) signatures was constructed to classify patients into high- and low-risk groups. The risk score was an independent prognostic indicator of OS (hazard ratio > 1, P < 0.001). The genetic alteration analysis indicated that the nine DE-DRGs in the signature were changed in 63 required samples (100%), and the major alteration was missense mutation. Function enrichment analysis revealed that the immune response and mtotic sister chromatid segregation were the main biological processes. The high-risk group had higher immune score than the low-risk group. What’s more, low-risk patients were more sensitive to selumetinib and dasatinib. The nine DE-DRGs signature was significantly associated with OS and provided a new insight for the diagnosis and treatment of CRC.
format Online
Article
Text
id pubmed-9050689
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90506892022-04-30 Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer Song, Dingli Zhang, Dai Chen, Sisi Wu, Jie Hao, Qian Zhao, Lili Ren, Hong Du, Ning Sci Rep Article Colorectal cancer (CRC) is the third most common malignant tumor. DNA damage plays a crucial role in tumorigenesis, and abnormal DNA repair pathways affect the occurrence and progression of CRC. In the current study, we aimed to construct a DNA repair-related gene (DRG) signature to predict the overall survival (OS) of patients with CRC patients. The differentially expressed DRGs (DE-DRGs) were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The prognostic gene signature was identified by univariate Cox regression and least absolute shrinkage and selection operator (LASSO)-penalized Cox proportional hazards regression analysis. The predictive ability of the model was evaluated using the Kaplan–Meier curves and time-dependent receiver operating characteristic (ROC) curves. The gene set enrichment analysis (GSEA) was performed to explore the underlying biological processes and signaling pathways. ESTIMATE and CIBERSORT were implemented to estimate the tumor immune score and immune cell infiltration status between the different risk group. The half-maximal inhibitory concentration (IC50) was evaluated to representing the drug response of this signature. Nine DE-DRGs (ESCO2, AXIN2, PLK1, CDC25C, IGF1, TREX2, ALKBH2, ESR1 and MC1R) signatures was constructed to classify patients into high- and low-risk groups. The risk score was an independent prognostic indicator of OS (hazard ratio > 1, P < 0.001). The genetic alteration analysis indicated that the nine DE-DRGs in the signature were changed in 63 required samples (100%), and the major alteration was missense mutation. Function enrichment analysis revealed that the immune response and mtotic sister chromatid segregation were the main biological processes. The high-risk group had higher immune score than the low-risk group. What’s more, low-risk patients were more sensitive to selumetinib and dasatinib. The nine DE-DRGs signature was significantly associated with OS and provided a new insight for the diagnosis and treatment of CRC. Nature Publishing Group UK 2022-04-28 /pmc/articles/PMC9050689/ /pubmed/35484177 http://dx.doi.org/10.1038/s41598-022-10561-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Song, Dingli
Zhang, Dai
Chen, Sisi
Wu, Jie
Hao, Qian
Zhao, Lili
Ren, Hong
Du, Ning
Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title_full Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title_fullStr Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title_full_unstemmed Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title_short Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer
title_sort identification and validation of prognosis-associated dna repair gene signatures in colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050689/
https://www.ncbi.nlm.nih.gov/pubmed/35484177
http://dx.doi.org/10.1038/s41598-022-10561-w
work_keys_str_mv AT songdingli identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT zhangdai identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT chensisi identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT wujie identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT haoqian identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT zhaolili identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT renhong identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer
AT duning identificationandvalidationofprognosisassociateddnarepairgenesignaturesincolorectalcancer